A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 07 Mar 2018 According to a Daiichi Sankyo Company media release, the first part of the study is expected to enroll approximately 50 patients, following the outcome of the first part of the study two additional exploratory cohorts may proceed to enroll patients whose tumors have lower levels of HER2-expression.
- 07 Mar 2018 According to a Daiichi Sankyo Company media release, the first patient has been dosed in this global phase 2 study.
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.